Ravi Iyengar is an Endocrinology/Metabolic physician affiliated with University of California San Diego Medical Center. OpenAlex indexes 9 publications with 200 citations (h-index 3).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
200 W Arbor Dr
San Diego, CA 921039000
Telephone
800-926-8273Provider last certified this registry record 16 Feb 2023.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Abbott LaboratoriesProgram year20254 payments
- Xeris Pharmaceuticals, Inc.Program year20252 payments
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
51.8%GLP-1 receptor agonist31.5%Ozempic56%Trulicity27%Mounjaro17%Part D<11 patientsInsulin Analog12.2%Lantus Solostar49%Humalog Kwikpen U-10030%Basaglar Kwikpen U-10021%Part D<11 patients+ 3 more classes in this area
Hormonal (systemic)
31.5%l-Thyroxine14.9%Levothyroxine Sodium100%Part D≥25 patientsParathyroid Hormone Analog7.2%Teriparatide100%Part D<11 patients+ 2 more classes in this area
Sensory organs
6.6%Corticosteroid6.6%Hydrocortisone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Easing the burden: exploring the role of long-acting testosterone formulations in gender-affirming care
Frontiers in Public Health
2026 - Comparative Retrospective Analysis of Ovarian Cancer Treatment Outcomes: Neoadjuvant Therapy with and without Surgical Intervention
Indian Journal of Surgical Oncology
2024 - Case Report: Invasive Endometrial Cancer in a Trans Man and Risk of Testosterone Therapy
Journal of the Endocrine Society
2021 - SAT-245 A Rare Case of Clival Primary Diffuse Large B-Cell Lymphoma Presenting with Panhypopituitarism and Unmasked Diabetes Insipidus
Journal of the Endocrine Society
2020 - Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports
Clinical Diabetes and Endocrinology
2019
Similar KOLs
Other experts from the same institution or the same specialty.
Marc Schuckit, MD
University of California San Diego Medical Center
Bobby Korn, MD
University of California San Diego Medical Center
Naohide Sakakibara, MD
University of California San Diego Medical Center
Jeffrey Melancon, MD, PhD
University of California San Diego Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”